Icon

ExecSummary

Exec Summary-Is My Molecule Suitable for an Orally Disintegrating Tablet


Orally Disintegrating Tablets (ODTs) are a patient-preferred dose form that offers additional potential benefits related to pregastric API delivery and absorption. While new drug products may benefit from ODT formulation beginning with product launch, ODT formulation can also play a role in life cycle management of approved products. API suitability for an ODT is dependent on multiple factors, including delivery target and physicochemical profile. New advances are also being developed to expand the potential of this technology.

Learn more about:

Several manufacturing processes are used to produce ODTs

ODT dosing avoids first pass metabolism

ODT selection targets the oral mucosa

Line

Why Catalent?

Catalyst + Talent

Catalent is the global leader in enabling pharma, biotech, and consumer health partners to optimize product development, launch, and full life-cycle supply for patients around the world. With broad and deep scale and expertise in development sciences, delivery technologies, and multi-modality manufacturing, Catalent is a preferred industry partner for personalized medicines, consumer health brand extensions, and blockbuster drugs. Catalent helps accelerate over 1,000 partner programs and launch over 150 new products every year. Its flexible manufacturing platforms at over 50 global sites supply over 70 billion doses of more than 7,000 products to over 1,000 customers annually. Catalent’s expert workforce exceeds 17,000, including more than 2,500 scientists and technicians. Headquartered in Somerset, New Jersey, the company generated $4 billion in revenue in its 2021 fiscal year. For more information, visit www.catalent.com.

More products. Better treatments. Reliably supplied.™